C(OC([N:8]1[C@H:12]([C:13](O)=O)[C@H:11]([CH:16](C)C)[O:10]C1(C)C)=O)(C)(C)C.[NH2:21][C:22]1[CH:23]=[C:24]([C:29]2[CH:34]=[CH:33][C:32]([C:35]#[N:36])=[CH:31][CH:30]=2)[CH:25]=[CH:26][C:27]=1[NH2:28]>>[NH2:8][C@H:12]([C:13]1[NH:28][C:27]2[CH:26]=[CH:25][C:24]([C:29]3[CH:34]=[CH:33][C:32]([C:35]#[N:36])=[CH:31][CH:30]=3)=[CH:23][C:22]=2[N:21]=1)[C@@H:11]([OH:10])[CH3:16]The title compound was prepared according to Method 4 using (4S,5S)-3-(tert-butoxycarbonyl)-5-isopropyl-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid (Preparation 59B) and 3′,4′-diaminobiphenyl-4-carbonitrile (Preparation 82). The reaction mixture was concentrated in vacuo and purified by SCX-2 cartridge (16 mg, 72%).
読み込み中…